Abstract

An international team plans to begin a Phase I trial of a small molecule targeting FGFR1 after discovering that the target is overexpressed in squamous cell lung cancer. The findings further reinforce work on the pathway by Five Prime Therapeutics.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call